The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors

• Main Authors: Ko T.K., Chuah C.T., Huang J.W., Ng K.-P., Ong S.T.
• Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
• Format: Article
• Published: 2020
• Subjects: BCR ABL protein; BH3 protein; imatinib; navitoclax; protein bcl 2; protein bcl xl; protein tyrosine kinase inhibitor; venetoclax; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; aniline derivative; antineoplastic agent; benzamide derivative; fused heterocyclic rings; piperazine derivative; protein kinase inhibitor; pyrimidine derivative; sulfonamide; Article; blood toxicity; cell death; chronic myeloid leukemia; drug activity; human; human cell; IC50; maximum tolerated dose; protein expression; thrombocyte lifespan; thrombocytopenia; antagonists and inhibitors; apoptosis; cancer stem cell; drug effects; drug resistance; drug screening; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; metabolism; tumor cell line; Aniline Compounds; Antineoplastic Agents; Apoptosis; Benzamides; Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Tumor Stem Cell Assay
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/174163
• Institution: National University of Singapore

10.18632/oncotarget.1925